(IN BRIEF) SCHOTT Pharma, Gerresheimer, and Stevanato Group have formed the “Alliance for RTU” to promote the adoption of ready-to-use (RTU) vials and cartridges within the pharmaceutical industry. This strategic alliance aims to streamline pharmaceutical manufacturing, improve operational efficiency, and … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Alliance for RTU, cartridges, Gerresheimer, partnership, Ready-to-Use Packaging Solutions, safety, SCHOTT Pharma, Stevanato Group, sustainability, vials
(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active lupus nephritis. The study found that patients receiving Gazyva/Gazyvaro, in combination with standard therapies, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Dr. Brad H. Rovin, Gazyva, kidney disease patients, Levi Garraway, lupus nephritis, Roche, safety
(IN BRIEF) Krka employees participated in the European Mobility Week for the ninth consecutive year, promoting sustainable commuting through the company’s Car-Free Day campaign. Employees from 13 countries adopted eco-friendly travel methods such as cycling, public transport, and walking. This … Read the full press release
Posted in Business, Environment, Financial, Industrial, Investment, Management, Media, News, Pharma & Biotech, Slovenia, Technology, Transportation & Logistics
Tagged Car-Free Day, cycling, electric truck, Krka, partnership, public transport, sustaianbility, walking
(IN BRIEF) Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older. Pending final approval from the European Commission, the vaccine will … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged BioNTech, COVID-19 vaccine, New York, Omicron KP.2, partnership, Pfizer, safety, sustainability
(IN BRIEF) FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making it the first flu vaccine of its kind to be used at home. Adults up to 49 years old … Read the full press release
(IN BRIEF) Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of novel antifungal and antibacterial treatments. The agreement provides an initial USD 29 million, with the potential … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antibacterial Treatments, antifungal, BAL2062, Basilea, Biomedical Advanced Research and Development Authority (BARDA), David Veitch, fosmanogepix, partnership, sustainability, USA
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be fatal without treatment. The approval is based on results from the MANDARA … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Dr. Michael Wechsler, Eosinophilic Granulomatosis with Polyangiitis (EGPA), Fasenra, FDA, Joyce Kullman, Ruud Dobber, safety, vasculitis
(IN BRIEF) Abolis Biotechnologies has secured €35 million from a global consortium of investors, including Evonik Venture Capital, BOLD (L’Oréal’s fund), and the DeepTech & Climate Fonds. This investment will help the company expand its biomanufacturing capabilities and bring sustainable, … Read the full press release
Posted in Business, Chemicals, Environment, Financial, France, Germany, Government, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Abolis Biotechnologies, BOLD (Business Opportunities for L’Oréal Development), Clay Capital, DeepTech & Climate Fonds, Evonik, France, investment, Netherlands, partnership, Singapore, sustainability
(IN BRIEF) GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses against influenza A and B strains in both younger and older adults. The trial met success criteria … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged flu vaccine, GSK, mRNA, Phase II, Phase III, safety, Tony Wood
(IN BRIEF) GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and SWIFT-2 phase III trials. Administered every six months, it also demonstrated a 72% reduction in hospitalizations and emergency visits, offering … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged David Jackson, Depemokimab, GSK, Phase III Trials, safety, Severe Asthma Attacks, SWIFT-1, SWIFT-2
(IN BRIEF) AstraZeneca has completed clinical studies to transition Breztri, its inhaled treatment for COPD, to a next-generation propellant with 99.9% lower Global Warming Potential. This change aligns with AstraZeneca’s commitment to reducing its environmental impact through its Ambition Zero … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breztri, COPD, eco-friendly, Honeywell, Low-Impact Inhalers, partnership, Professor Omar Usmani, sustainability
(IN BRIEF) Krka celebrated its 70th anniversary by unveiling a new book with an inscription alongside its “Girl with the Growing Book” sculpture. The new book’s inscription reflects the company’s commitment to ambitious ideas, professionalism, creativity, and courage. Slovenian President … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged 70 Years, Dr. Nataša Pirc Musar, INNOVATION, Jože Colarič, Jurij Smole, Krka, sculpture
(IN BRIEF) Boehringer Ingelheim and CDR-Life have reported positive results from the Phase I trial of BI 771716, an investigational treatment for geographic atrophy (GA), a severe form of age-related macular degeneration. The antibody fragment met its primary safety endpoints, … Read the full press release
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Basilea Pharmaceutica, Cresemba®, David Veitch, Financial, fungal infections, investment
(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a … Read the full press release
(IN BRIEF) AstraZeneca will present significant cancer research at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress. Highlights include new data on the effectiveness of Imfinzi in bladder cancer, a novel … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, cancer research, European Society for Medical Oncology (ESMO), Imfinzi, Susan Galbraith, World Conference on Lung Cancer (WCLC)
(IN BRIEF) Sanofi’s phase 3 study for its drug tolebrutinib has shown promising results in treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no current approved therapies. The HERCULES study revealed that tolebrutinib successfully delayed disability progression in … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged activated microglia, annualized relapse rate (ARR), B lymphocytes, brain-penetrant BTK inhibitor, central nervous system (CNS), confirmed disability progression (CDP), Copenhagen, Denmark, disability accumulation, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), GEMINI 1 and 2 phase 3 studies, HERCULES phase 3 study, Houman Ashrafian, innate immunity, multiple sclerosis, neuroinflammation, non-relapsing secondary progressive MS (nrSPMS), PERSEUS phase 3 study, primary progressive MS, Sanofi, teriflunomide, tolebrutinib
(IN BRIEF) Roche has received approval from the European Commission for PiaSky® (crovalimab), a novel treatment for paroxysmal nocturnal haemoglobinuria (PNH), making it the first monthly subcutaneous (SC) treatment available in the European Union. PiaSky, which can be self-administered by … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged EU, Paroxysmal Nocturnal Haemoglobinuria (PNH), PiaSky, Roche, safety
(IN BRIEF) Brenntag has expanded its presence in Brazil’s Life Science market with the acquisition of specialty chemicals distributors PIC and PharmaSpecial. The deal, which adds an Applications & Innovation Center and two laboratories to Brenntag’s network, will enhance its … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acquisition, Brazil, Brenntag, Fabio Morais, François Bleger, Life Science Market, partnership, PIC and PharmaSpecial, sustainability, Switzerland, Torsten Walz
(IN BRIEF) SISTO Armaturen S.A., part of the KSB Group, has developed the SISTO-CM1300, an automated multi-port valve designed to optimize pharmaceutical production processes. This valve automates the switching of fluids in cleaning and sterilization processes, reducing the risk of … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Luxembourg, Management, News, Pharma & Biotech, Technology
Tagged KSB, Luxembourg, Multi-Port Valve, partnership, Pharmaceutical Production, SISTO Armaturen S.A., sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?